Enhanced Pharmaceutically Active Compounds Productivity from Streptomyces SUK 25: Optimization, Characterization, Mechanism and Techno-Economic Analysis.

The present research aimed to enhance the pharmaceutically active compounds' (PhACs') productivity from Streptomyces SUK 25 in submerged fermentation using response surface methodology (RSM) as a tool for optimization. Besides, the characteristics and mechanism of PhACs against methicillin-resistant Staphylococcus aureus were determined. Further, the techno-economic analysis of PhACs production was estimated. The independent factors include the following: incubation time, pH, temperature, shaker rotation speed, the concentration of glucose, mannitol, and asparagine, although the responses were the dry weight of crude extracts, minimum inhibitory concentration, and inhibition zone and were determined by RSM. The PhACs were characterized using GC-MS and FTIR, while the mechanism of action was determined using gene ontology extracted from DNA microarray data. The results revealed that the best operating parameters for the dry mass crude extracts production were 8.20 mg/L, the minimum inhibitory concentrations (MIC) value was 8.00 µg/mL, and an inhibition zone of 17.60 mm was determined after 12 days, pH 7, temperature 28 °C, shaker rotation speed 120 rpm, 1 g glucose /L, 3 g mannitol/L, and 0.5 g asparagine/L with R2 coefficient value of 0.70. The GC-MS and FTIR spectra confirmed the presence of 21 PhACs, and several functional groups were detected. The gene ontology revealed that 485 genes were upregulated and nine genes were downregulated. The specific and annual operation cost of the production of PhACs was U.S. Dollar (U.S.D) 48.61 per 100 mg compared to U.S.D 164.3/100 mg of the market price, indicating that it is economically cheaper than that at the market price.

A review of pharmaceutical occurrence and pathways in the aquatic environment in the context of a changing climate and the COVID-19 pandemic.

Active pharmaceutical ingredients (APIs) are increasingly being identified as contaminants of emerging concern (CECs). They have potentially detrimental ecological and human health impacts but most are not currently subject to environmental regulation. Addressing the life cycle of these pharmaceuticals plays a significant role in identifying the potential sources and understanding the environmental impact that pharmaceuticals may have in surface waters. The stability and biological activity of these "micro-pollutants" can lead to a pseudo persistence, with ensuing unknown chronic behavioural and health-related effects. Research that investigates pharmaceuticals predominantly focuses on their occurrence and effect within surface water environments. However, this review will help to collate this information with factors that affect their environmental concentration. This review focuses on six pharmaceuticals (clarithromycin, ciprofloxacin, sulfamethoxazole, venlafaxine, gemfibrozil and diclofenac), chosen because they are heavily consumed globally, have poor removal rates in conventional activated sludge wastewater treatment plants (CAS WWTPs), and are persistent in the aquatic environment. Furthermore, these pharmaceuticals are included in numerous published prioritisation studies and/or are on the Water Framework Directive (WFD) "Watch List" or are candidates for the updated Watch List (WL). This review investigates the concentrations seen in European Union (EU) surface waters and examines factors that influence final concentrations prior to release, thus giving a holistic overview on the source of pharmaceutical surface water pollution. A period of 10 years is covered by this review, which includes research from 2009-2020 examining over 100 published studies, and highlighting that pharmaceuticals can pose a severe risk to surface water environments, with each stage of the lifecycle of the pharmaceutical determining its concentration. This review additionally highlights the necessity to improve education surrounding appropriate use, disposal and waste management of pharmaceuticals, while implementing a source directed and end of pipe approach to reduce pharmaceutical occurrence in surface waters.

Systematic assessment of extraction of pharmaceuticals and personal care products in water and sediment followed by liquid chromatography-tandem mass spectrometry.

Two solid-phase extraction methods were systematically studied to determine 32 pharmaceuticals and personal care products in water and sediments by ultrahigh-performance liquid chromatography-tandem mass spectrometry. One involves HLB cartridges activated with sodium dodecyl sulfate before the passage of the sample to form an ion pair with cationic analytes, and the other uses mixed HLB-cation exchange cartridges. The accuracy of the sodium dodecyl sulfate method was good for most compounds (recoveries of 61-120% with relative standard deviation less than 23%). However, the recoveries for atorvastatin, codeine, paracetamol, flufenamic acid, and salicylic acid were approximately 50% and for omeprazole and triclocarban were even lower (from 0 to 12%). The detection limits were 1.65-25 ng L-1 in water and 0.33-4.00 ng g-1 (dry weight) in sediment. The recoveries for the mixed-mode cartridge (Strata-X-CW) method ranged from 57% to 120% with relative standard deviation less than 21%, with the exception of codeine [25% (water)], metformin [11% (sediment)], paracetamol [48% (sediment)], and salicylic acid [32% (sediment)]. The detection limits were 1.65-38.35 ng L-1 in water and 0.33-10 ng g-1 (dry weight) in sediment. Both methods followed the same pattern when applied to water. For sediments, the recoveries, which offer good performance, were not very high, although 60% of the compounds had recoveries greater 80%. The methods were applied to the analysis of surface water and sediments from the Albufera Natural Park (Spain). Twenty-seven of 32 analytes were detected in the samples analyzed.

Influence of organic modifier and separation modes for lipophilicity assessment of drugs using thin layer chromatography indices.

Lipophilicity constitutes one of the most important physicochemical properties in the design and development of drug molecules. In the present work thin layer chromatography (TLC) has been utilized to evaluate lipophilicity of 11 representative drugs, which included six proton pump inhibitors (omeprazole, pantoprazole, rabeprazole, lansoprazole, ilaprazole, and tenatoprazole), an anti-vertigo drug, betahistine, nonsteroidal anti-inflammatory drug, ibuprofen, anti-malarial drug, atovaquone, an anti-HIV agent, atazanavir and a hormonal drug, calcitriol. Normal as well as reversed-phase separation modes were evaluated to study the effect of different organic modifiers for the estimation of lipophilicity. The quantitative descriptor of lipophilicity, the partition coefficient (logP) was estimated by suitably optimizing the solvent systems for both the modes. The best mobile phase pairs for NPTLC and RPTLC were toluene-acetonitrile and water-methanol respectively. Principal component analysis, hierarchical cluster analysis, as well as non-parametric methods like sum of ranking differences and generalized pair wise correlation revealed the dominant pattern in the data. The results obtained from both the separation modes were comparable and were in good agreement with the computational data for all the drugs.

A novel one-pot strategy to prepare ß-cyclodextrin functionalized capillary monoliths for enantioseparation of basic drugs.

With native ß-cyclodextrin (ß-CD) added into the polymerization mixture directly, a novel, convenient and low-cost one-pot strategy was developed to prepare the ß-CD functionalized organic polymer monolithic capillary column. Diazabicyclo[5.4.0]undec-7-ene (DBU) as a basic catalyst for the ring opening reaction between ß-CD and glycidyl methacrylate (GMA) was introduced into the polymerization system for the first time. Thereby, two consecutive reactions namely the in situ methacrylation of ß-CD and copolymerization reaction can be achieved in one pot. The preparation conditions including the type and composition of porogens，the ratio of functional monomer to crosslinker and amount of 2-acrylamido-2-methyl propane sulfonic acid (AMPS) were optimized. The specific surface area and morphology of the prepared monolith were characterized using scanning electron microscopy (SEM) and nitrogen adsorption analysis, respectively. Raman spectroscopy and nuclear magnetic resonance (NMR) spectroscopy confirmed that ß-CD was covalently bonded onto the monolith successfully. Then, the monolithic column was applied to enantioseparation of six basic drugs in capillary electrochromatography (CEC). Under the optimal conditions, tropicamide, homatropine, homatropine methylbromide, brompheniramine, chlorpheniramine and clorprenaline were all totally separated with the resolution (Rs) values of 2.84, 4.70, 4.61, 3.01, 2.57 and 2.33, respectively. Furthermore, the column demonstrated satisfactory stability and repeatability of retention time and enantioselectivity using homatropine as model analyte.

Versatile and on-demand biologics co-production in yeast.

Current limitations to on-demand drug manufacturing can be addressed by technologies that streamline manufacturing processes. Combining the production of two or more drugs into a single batch could not only be useful for research, clinical studies, and urgent therapies but also effective when combination therapies are needed or where resources are scarce. Here we propose strategies to concurrently produce multiple biologics from yeast in single batches by multiplexing strain development, cell culture, separation, and purification. We demonstrate proof-of-concept for three biologics co-production strategies: (i) inducible expression of multiple biologics and control over the ratio between biologic drugs produced together; (ii) consolidated bioprocessing; and (iii) co-expression and co-purification of a mixture of two monoclonal antibodies. We then use these basic strategies to produce drug mixtures as well as to separate drugs. These strategies offer a diverse array of options for on-demand, flexible, low-cost, and decentralized biomanufacturing applications without the need for specialized equipment.

Monitoring enzymatic degradation of emerging contaminants using a chip-based robotic nano-ESI-MS tool.

Up to now, knowledge of enzymes capable of degrading various contaminants of emerging concern (CEC) is limited, which is especially due to the lack of rapid screening methods. Thus, a miniaturized high-throughput setup using a chip-based robotic nanoelectrospray ionization system coupled to mass spectrometry has been developed to rapidly screen enzymatic reactions with environmentally relevant CECs. Three laccases, two tyrosinases, and two peroxidases were studied for their ability to transform ten pharmaceuticals and benzotriazole. Acetaminophen was most susceptible to enzymatic conversion by horseradish peroxidase (HRP), laccase from Trametes versicolor (LccTV), and a tyrosinase from Agaricus bisporus (TyrAB). Diclofenac and mefenamic acid were converted by HRP and LccTV, whereas sotalol was solely amenable to HRP conversion. Benzotriazole, carbamazepine, gabapentin, metoprolol, primidone, sulfamethoxazole, and venlafaxine remained persistent in this study. The results obtained here emphasize that enzymes are highly selective catalysts and more effort is required in the use of fast monitoring technologies to find suitable enzyme systems. Despite the methodological limitations discussed in detail, the automated tool provides a routine on-line screening of various enzymatic reactions to identify potential enzymes that degrade CECs. Graphical abstract A chip-based robotic nano-ESI-MS tool to rapidly monitor enzymatic degradation of environmentally relevant emerging contaminants.

Simplified solid-phase extraction procedure combined with liquid chromatography tandem-mass spectrometry for multiresidue assessment of pharmaceutical compounds in environmental liquid samples.

To follow the twelve "green analytical chemistry" (GAC) principles, it is necessary to continuously develop analytical extraction and determination methodologies to assess the presence of micropollutants, such as pharmaceuticals, in environmental samples. A reduction in the analysis time and solvent quantity, which is one of the GAC principles, has been achieved through a simplified solid-phase extraction (SPE) procedure combined with high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the determination of twenty-three pharmaceuticals in liquid environmental samples using N-vinylpyrrolidone-divinylbenzene copolymer (OASIS HLB) cartridges. The optimal SPE conditions were studied. In these optimized conditions, 82.6% of the data have a median recovery above 70% for all compounds in each sample. The relative standard deviations (RSDs) were below 14.4% and 22.0% for intra- and inter-day repeatability, respectively. Method detection limits (MDLs) and method quantification limits (MQLs) ranged from 0.011 to 188ngL-1 and from 0.033 to 628ngL-1, respectively. The applicability of the method was evaluated in real samples from natural and conventional wastewater treatment plants (WWTPs), and results were obtained in concentration ranges from 0.013 to 91.5µgL-1 and from 0.004 to 49.1µgL-1, respectively.

Highly engineered biocatalysts for efficient small molecule pharmaceutical synthesis.

Technologies for the engineering of biocatalysts for efficient synthesis of pharmaceutical targets have advanced dramatically over the last few years. Integration of computational methods for structural modeling, combined with high through put methods for expression and screening of biocatalysts and algorithms for mining experimental data, have allowed the creation of highly engineered biocatalysts for the efficient synthesis of pharmaceuticals. Methods for the synthesis of chiral alcohols and amines have been particularly successful, along with the creation of non-natural activities for such desirable reactions as cyclopropanation and esterification.

Environmental impact of pharmaceuticals from Portuguese wastewaters: geographical and seasonal occurrence, removal and risk assessment.

The occurrence, fate, geographical and seasonal influence and environmental risk assessment of eleven of the most consumed pharmaceuticals in Portugal were studied in wastewater treatment plants (WWTPs) influents and (WWI) and effluents (WWE). WWI and WWE samples, from two sampling campaigns (spring and summer), in 2013, were evaluated in 15 different WWTPs across the country, by solid phase extraction (SPE) and liquid chromatography coupled with tandem mass detection (LC-MS-MS). Lipid regulators were the most frequently found in WWI and WWE (184.1 and 22.3mg/day/1000 inhab., respectively), followed by anti-inflammatories (1339.4 and 15.0mg/day/1000 inhab., respectively), and antibiotics (330.7 and 68.6 mg/day/1000 inhab., respectively). Anxiolytics were the least detected with 3.3 and 3.4 mg/day/1000 inhab. in WWI and WWE, respectively. The mass loads, both in WWI and WWE, were higher in summer than those found during the spring season, being remarkable the high values registered in a region where population triplicates in this time of the year. The mean removal efficiency achieved was of 94.5%, nonetheless, between the different therapeutic groups, as well as within each group, important variations in removal were observed, going from not eliminated to 100%. In the summer higher efficiencies were observed regarding lipid regulators and antibiotics. Furthermore, an important outcome was the evaluation, by means of risk quotients (RQs), of the potential ecotoxicological risk posed by the selected pharmaceuticals to different aquatic organisms, exposed to the effluents studied. Ciprofloxacin, bezafibrate, gemfibrozil, simvastatin and diclofenac showed RQs higher than one, being expected that these pharmaceuticals might pose a threat to the three trophic levels (algae, daphnids and fish) evaluated. These results highlight the importance of these monitoring studies, as required by the Directive 2013/39/EU, in order to minimize their aquatic environmental contamination and support future prioritization measures.

Determination of rate constants and equilibrium constants for solution-phase drug-protein interactions by ultrafast affinity extraction.

A method was created on the basis of ultrafast affinity extraction to determine both the dissociation rate constants and equilibrium constants for drug-protein interactions in solution. Human serum albumin (HSA), an important binding agent for many drugs in blood, was used as both a model soluble protein and as an immobilized binding agent in affinity microcolumns for the analysis of free drug fractions. Several drugs were examined that are known to bind to HSA. Various conditions to optimize in the use of ultrafast affinity extraction for equilibrium and kinetic studies were considered, and several approaches for these measurements were examined. The dissociation rate constants obtained for soluble HSA with each drug gave good agreement with previous rate constants reported for the same drugs or other solutes with comparable affinities for HSA. The equilibrium constants that were determined also showed good agreement with the literature. The results demonstrated that ultrafast affinity extraction could be used as a rapid approach to provide information on both the kinetics and thermodynamics of a drug-protein interaction in solution. This approach could be extended to other systems and should be valuable for high-throughput drug screening or biointeraction studies.

Evaluation of the QuEChERS method for the extraction of pharmaceuticals and personal care products from drinking-water treatment sludge with determination by UPLC-ESI-MS/MS.

A modified version of the QuEChERS method has been evaluated for the determination of 21 pharmaceuticals and 6 personal care products (PPCPs) in drinking-water sludge samples by employing ultra high liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The performance of the method was evaluated through linearity, recovery, precision (intra-day), method detection and quantification limits (MDL and MQL) and matrix effect. The calibration curves prepared in acetonitrile and in the matrix extract showed a correlation coefficient ranging from 0.98 to 0.99. MQLs values were on the ng g(-1) order of magnitude for most compounds. Recoveries between 50% and 93% were reached with RSDs lower than 10% for most compounds. Matrix effect was almost absent with values lower than 16% for 93% of the compounds. By coupling a quick and simple extraction called QuEChERS with the UPLC-MS/MS analysis, a method that is both selective and sensitive was obtained. This methodology was successfully applied to real samples and caffeine and benzophenone-3 were detected in ng g(-1) levels.

Evaluating the efficiency of advanced wastewater treatment: target analysis of organic contaminants and (geno-)toxicity assessment tell a different story.

At a pilot scale wastewater treatment plant ozonation and powdered activated carbon filtration were assessed for their efficacy to remove trace organic contaminants from secondary treated effluents. A chemical analysis of 16 organic compounds was accompanied by a comprehensive suite of in vitro and in vivo bioassays with the focus on genotoxicity to account for the potential formation of reactive oxidation products. In vitro experiments were performed with solid phase extracted water samples, in vivo experiments with native wastewater in a flow through test system on site at the treatment plant. The chemical evaluation revealed an efficient oxidation of about half of the selected compounds by more than 90% at an ozone dose of 0.7 g/g DOC. A lower oxidizing efficiency was observed for the iodinated X-ray contrast media (49-55%). Activated carbon treatment (20 mg/L) was less effective for the removal of most pharmaceuticals monitored. The umuC assay on genotoxicity delivered results with about 90% decrease of the effects by ozonation and slightly lower efficiency for PAC treatment. However, the Ames test on mutagenicity with the strain YG7108 revealed a consistent and ozone-dose dependent increase of mutagenicity after wastewater ozonation compared to secondary treatment. Sand filtration as post treatment step reduced the ozone induced mutagenicity only partly. Also the fish early life stage toxicity test revealed an increase in mortality after ozonation and a reduced effect after sand filtration. Only activated carbon treatment reduced the fish mortality compared to conventional treatment on control level. Likewise the in vivo genotoxicity detected with the comet assay using fish erythrocytes confirmed an increased (geno-)toxicity after ozonation, an effect decrease after sand-filtration and no toxic effects after activated carbon treatment. This study demonstrates the need for a cautious selection of methods for the evaluation of advanced (oxidative) treatment technologies and of the effectiveness of post-treatments for elimination of adverse effects caused by oxidative treatments case by case.

Assessment of quantitative structural property relationships for prediction of pharmaceutical sorption during biological wastewater treatment.

In this study, we critically examined the available data related to pharmaceutical (PhAC) sorption in biological treatment processes. Using these data, we developed and assessed single and polyparameter quantitative structural activity models to better understand the role of sorption in PhAC attenuation. In contrast to other studies, our analysis suggests that values of the sorption coefficient (KD) are poorly correlated to single parameter models employing logKOW or the apparent partition coefficient (i.e., KOW corrected to the experimental pH). Results from the development of polyparameter models suggest that the range of functional moieties typically incorporated in PhAC molecules offers a diverse set of interactions between PhAC and sludge surface (e.g., hydrogen bonding, electrostatic interactions, and hydrophobic interactions). Of particular importance is the role of dissociation and resulting charge(s) of a PhAC in solution. Results demonstrate that when developing predictive models it is advantageous to separate PhACs based upon the charge of the dominant species at the experimental pH. Yet, use a single model for PhACs which are negatively charged and uncharged may have practical utility. Performance of the polyparameter models, however, was found to plateau with a pred-R(2) between 0.50 and 0.60, even when six statistically relevant predictors are included. This outcome suggests that effective predictive models for PhAC sorption cannot include solely PhAC descriptors, rather they must incorporate critical properties related to the sorbent (i.e., mixed liquor) surface.

Scalable technology for the extraction of pharmaceutics: outcomes from a 3 year collaborative industry/academia research programme.

This paper reports on some of the key outcomes of a 3 year £1.5m Technology Strategy Board (TSB) funded research programme to develop a small footprint, versatile, counter-current chromatography purification technology and methodology which can be operated at a range of scales in both batch and continuous modes and that can be inserted into existing process plant and systems. Our consortium, integrates technology providers (Dynamic Extractions) and the scientific development team (Brunel) with end user needs (GSK & Pfizer), addressing major production challenges aimed at providing flexible, low capital platform technology driving substantial cost efficiency in both drug development and drug manufacturing processes. The aims of the Technology Strategy Board's high value manufacturing programme are described and how the academic/industry community were challenged to instigate step changes in the manufacturing of high value pharmaceuticals. This paper focusses on one of the themes of the TSB research programme, "Generate a Comprehensive Applications Portfolio". It outlines 15 applications from this portfolio that can be published in the public domain and gives four detailed case studies illustrating the range of application of the technology on the separation of (1) isomers, (2) polar compounds, (3) crude mixtures and (4) on the removal of impurities. Two of these case studies that were scaled up demonstrate between 10 and 20% lower solvent usage and were projected to have significant cost savings compared to conventional solid phase silica gel chromatography at procss scale demonstrating that the latest high performance countercurrent chromatography technology is a competitive platform technolgy for the pharmaceutical industry.

Comparative and integrative environmental assessment of advanced wastewater treatment processes based on an average removal of pharmaceuticals.

Pharmaceuticals are normally barely removed by conventional wastewater treatments. Advanced technologies as a post-treatment, could prevent these pollutants reaching the environment and could be included in a centralized treatment plant or, alternatively, at the primary point source, e.g. hospitals. In this study, the environmental impacts of different options, as a function of several advanced treatments as well as the centralized/decentralized implementation options, have been evaluated using Life Cycle Assessment (LCA) methodology. In previous publications, the characterization of the toxicity of pharmaceuticals within LCA suffers from high uncertainties. In our study, LCA was therefore only used to quantify the generated impacts (electricity, chemicals, etc.) of different treatment scenarios. These impacts are then weighted by the average removal rate of pharmaceuticals using a new Eco-efficiency Indicator EFI. This new way of comparing the scenarios shows significant advantages of upgrading a centralized plant with ozonation as the post-treatment. The decentralized treatment option reveals no significant improvement on the avoided environmental impact, due to the comparatively small pollutant load coming from the hospital and the uncertainties in the average removal of the decentralized scenarios. When comparing the post-treatment technologies, UV radiation has a lower performance than both ozonation and activated carbon adsorption.

Interview: challenges faced by the modern bioanalytical laboratory.

Timothy Sangster (Charles River Laboratories) and Mike Oliver (Thermo Fisher Scientific) speak to Thomas Payne at Bioanalysis in September 2012 about the challenges faced by the modern bioanalytical laboratory. Timothy Sangster has been with Charles River Laboratories since September 2009. Having worked for Quintiles, Pharmacia, Astrazeneca and Huntingdon Life Sciences, he has gained experience over 17 years in both CRO and pharmaceutical environments, and also in both Europe and the USA. Specific areas of interest over the past years have been microchromatography, sample preparation and matrix effects, to name a few. Mike Oliver has held the position of Global Product Manager for sample preparation at Thermo Fisher Scientific since 2010, being responsible for the development and introduction of new innovative technologies such as SOLA™ to the market place. Prior to this role, Mike has worked for two leading MS vendors over a 9­year period, being responsible for biotechnology sales within the UK and providing application solutions for proteomic and metabolic workflows based on high-resolution LC-MS platforms, respectively. Mike holds a PhD in MS and Biochemistry from the MS Research Unit, University of Wales, Swansea, UK.

Is it better to remove pharmaceuticals in decentralized or conventional wastewater treatment plants? A life cycle assessment comparison.

After ingestion, pharmaceuticals are excreted unchanged or metabolized. They subsequently arrive in conventional wastewater treatment plants and are then released into the environment, often without undergoing any degradation. Conventional treatment plants can be upgraded with post treatment, alternatively the removal of pharmaceuticals could be achieved directly at point sources. In the European project PILLS, several solutions for decentralized treatment of pharmaceuticals at hospitals were investigated at both pilot plant and full scale, and were then compared to conventional and upgraded centralized treatment plants using Life Cycle Assessment (LCA). Within the scope of the study, pharmaceuticals were found to have a comparatively minor environmental impact. As a consequence, an additional post treatment does not provide significant benefits. In the comparison of post treatment technologies, ozonation and activated carbon performed better than UV. These results suffer however from high uncertainties due to the assessment models of the toxicity of pharmaceuticals in LCA. Our results should therefore be interpreted with caution. LCA is a holistic approach and does not cover effects or issues on a local level, which may be highly relevant. We should therefore apply the precautionary ALARA principle (As Low As Reasonably Achievable) and not conclude that the effect of pharmaceuticals is negligible in the environment.

Addressing the medicinal chemistry bottleneck: a lean approach to centralized purification.

The use of standardized lean manufacturing principles to improve drug discovery productivity is often thought to be at odds with fostering innovation. This manuscript describes how selective implementation of a lean optimized process, in this case centralized purification for medicinal chemistry, can improve operational productivity and increase scientist time available for innovation. A description of the centralized purification process is provided along with both operational and impact (productivity) metrics, which indicate lower cost, higher output, and presumably more free time for innovation as a result of the process changes described.

Fast and comprehensive multi-residue analysis of a broad range of human and veterinary pharmaceuticals and some of their metabolites in surface and treated waters by ultra-high-performance liquid chromatography coupled to quadrupole-linear ion trap tandem mass spectrometry.

The present work describes the development of an analytical method, based on automated off-line solid phase extraction (SPE) followed by ultra-high-performance liquid chromatography coupled to quadrupole linear ion trap tandem mass spectrometry (UPLC-QqLIT) for the determination of 81 pharmaceutical residues, covering various therapeutic groups, and some of their main metabolites, in surface and treated waters (influent and effluent wastewaters, river, reservoir, sea and drinking water). For unequivocal identification and confirmation, two selected reaction monitoring (SRM) transitions per compound are monitored. Quantification is performed by the internal standard approach, indispensable to correct matrix effects. Moreover, to obtain an extra tool for confirmation of positive findings, an information dependent acquisition (IDA) experiment was performed, with SRM as survey scan and an enhanced product ion (EPI) scan as dependent scan. Compound identification was carried out by library search, matching the EPI spectra achieved at one fixed collision energy with those present in a library. The main advantages of the method are automation and speed-up of sample preparation by the reduction of extraction volumes for some matrices, the fast separation of a big number of pharmaceuticals, its high sensitivity (limits of detection in the low ng/L range), selectivity, due to the use of tandem mass spectrometry, reliability since a significant number of isotopically labeled compounds are used as internal standards for quantification and finally, the analysis of tap, reservoir and sea waters, since information about occurrence of pharmaceuticals in these matrices is still sparse. As part of the validation procedure, the method developed was applied to the analysis of pharmaceutical residues in waste and surface waters from different sites in Catalonia (North East of Spain).